Inactivation of SNF5 cooperates with p53 loss to accelerate tumor formation in Snf5+/-;p53+/- mice

Molecular Carcinogenesis

Volumn 48, Issue 12, 2009, Pages 1139-1148

  DelBove, Jessica ^a   Kuwahara, Yasumichi ^b   Mora Blanco, E Lorena ^c   Godfrey, Virginia ^a,b   Funkhouser, William K ^a,b,d   Fletcher, Christopher D M ^e   Van Dyke, Terry ^a,b   Roberts, Charles W M ^c   Weissman, Bernard E ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c HARVARD UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Malignant rhabdoid tumor; p53; SNF5; SWI SNF

Indexed keywords

PROTEIN P53; PROTEIN S100B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SNF5; UNCLASSIFIED DRUG; VIMENTIN; CELL CYCLE PROTEIN; NONHISTONE PROTEIN; SMARCB1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER MODEL; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE INACTIVATION; GENETIC ENGINEERING; HAPLOTYPE; HETEROZYGOSITY; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RHABDOID TUMOR; SARCOMA; T CELL LYMPHOMA; TUMOR LOCALIZATION; TUMOR SUPPRESSOR GENE; ANIMAL; BONE TUMOR; GENETICS; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; SURVIVAL RATE;

MUS;

ANIMALS; BONE NEOPLASMS; CELL CYCLE PROTEINS; CHROMOSOMAL PROTEINS, NON-HISTONE; FEMALE; LYMPHOMA, T-CELL; MALE; MICE; MICE, KNOCKOUT; OSTEOSARCOMA; RHABDOID TUMOR; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 73349120265     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20568     Document Type: Article

References (42)

1. Haas J, Palmer N, Weinberg A, Beckwith J. Ultrastructure of malignant rhabdoid tumor of he kidney: A distinctive renal tumor of children. Hum Pathol 1981;12:646-657.
2. Kato H, Ohta S, Koshida S, et al. Expression of pericyte, mesangium and muscle markers in malignant rhabdoid tumor cell lines: Differentiation-induction using 5-azacytidine. Cancer Sci 2003;94:1059-1065.
3. Suzuki A, Ohta S, Shimada M. Gene expression of malignant rhabdoid tumor cell lines by reverse transcriptase-polymerase chain reaction. Diagn Mol Pathol 1997;6:326-332.
4. Gonzalez-Crussi F, Goldschmidt R, Hsueh W, Trujillo Y. Infantile sarcoma with intracytoplasmic filamentous inclusions. Distinctive tumor of possible histiocytic origin. Cancer 1982;49:2365-2375.
5. Lynch H, Shurin S, Dahms B, Izant RJ, Lynch J, Danes B. Paravertebral malignant rhabdoid tumor in infancy. In vitro studies of a familial tumor. Cancer 1983;52:290-296.
6. Tsuneyoshi M, Daimaru Y, Hashimoto H, Enjoji M. Malignant soft tissue neoplasms with the histologic features of renal rhabdoid tumors: An ultrastructural and immunohistochemical study. Hum Pathol 1985;16:1235-1242.
7. Biegel J, Zhou J, Rorke L, Stenstrom C, Wainwright L, Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999;59:74-79.
8. Rousseau-Merck MF, Versteege I, Legrand I, et al. hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors. Cancer Res 1999;59:3152-3156.
9. Sevenet N, Lellouch-Tubiana A, Schofield D, et al. Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum Mol Genet 1999;8:2359-2368.
10. Sevenet N, Sheridan E, Amram D, Schneider P, Handgretinger R, Delattre O. Constitutional mutation of the mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am J Hum Genet 1999;65:1342-1348.
11. Versteege I, Sevenet J, Lange M, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998;394:201-206.
12. Biegel J, Kalpana GV, Knudsen E, et al. The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors. Cancer Res 2002;61:323-328.
13. Rousseau-Merck MF, Fiette L, Klochendler-Yeivin A, Delattre O, Aurias A. Chromosome mechanisms and INI1 inactivation in human and mouse rhabdoid tumors. Cancer Genet Cytogenet 2005;157:127-133.
14. McKenna ES, Sansam CG, Cho YJ, et al. Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. Mol Cell Biol 2008;28:6223-6233.
15. Roberts C, Galusha S, McMenamin M, Fletcher C, Orkin SH. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc Natl Acad Sci USA 2000;97:13796-13800.
16. Roberts C, Leroux M, Fleming M, Orkin SH. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell 2002;2:415-425.
17. Guidi C. Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol Cell Biol 2001;21:3598-3603.
18. Klochendler-Yeivin A, Fiette L, FBarra J, Muchardt C, Babinet C, Yaniv M. The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression. EMBO Reports 2000;1:500-506.
19. Donehower L. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-221.
20. Sharpless NE, Bardeesy N, Lee KH, et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 2001;413:86-91.
21. Guidi CJ, Mudhasani R, Hoover K, et al. Functional interaction of the retinoblastoma and Ini1/Snf5 tumor suppressors in cell growth and pituitary tumorigenesis. Cancer Res 2006;66:8076-8082.
22. Chai J, Lu X, Godfrey V, et al. Tumor-specific cooperation of retinoblastoma protein family and Snf5 inactivation. Cancer Res 2007;67:3002-3009.
23. Isakoff M, Sansam C, Tamayo P, et al. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci USA 2005;102:17745-17750.
24. Kinoshita Y, Shiratsuchi H, Tamiya S, et al. Mutations of the p53 gene in malignant rhabdoid tumors of soft tissue and the kidney: Immunohistochemical and DNA direct sequencing analysis. J Cancer Res Clin Oncol 2001;127:351-358.
25. Rosson GB, Vincent TS, Oswald BW, Wright CF. Drug resistance in malignant rhabdoid tumor cell lines. Cancer Chemother Pharmacol 2002;49:142-148.
26. Klochendler-Yeivin A, Picarsky E, Yaniv M. Increased DNA damage sensitivity and apoptosis in cells lacking the Snf5/Ini1 subunit of the SWI/SNF chromatin remodeling complex. Mol Cell Biol 2006;26:2661-2674.
27. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7.
28. Saenz Robles MT, Symonds H, Chen J, Van Dyke T. Induction versus progression of brain tumor development: Differential functions for the pRB- and p53-targeting domains of simian virus 40 T antigen. Mol Cell Biol 1994;14:2686-2698.
29. Harvey M, McArthur MJ, Montgomery CA, Jr., Butel JS, Bradley A, Donehower LA. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet 1993;5:225-229.
30. Fanburg-Smith JC, Hengge M, Hengge UR, Smith JS, Jr., Miettinen M. Extrarenal rhabdoid tumors of soft tissue: A clinicopathologic and immunohistochemical study of 18 cases. Ann Diagn Pathol 1998;2:351-362.
31. Kaiserling E, Ruck P, Handgretinger R, Leipoldt M, Hipfel R. Immunohistochemical and cytogenetic findings in malignant rhabdoid tumor. Gen Diagn Pathol 1996;141:327-337.
32. Tsokos M, Kouraklis G, Chandra RS, Bhagavan BS, Triche TJ. Malignant rhabdoid tumor of the kidney and soft tissues. Evidence for a diverse morphological and immunocytochemical phenotype. Arch Pathol Lab Med 1989;113:115-120.
33. Vogel AM, Gown AM, Caughlan J, Haas JE, Beckwith JB. Rhabdoid tumors of the kidney contain mesenchymal specific and epithelial specific intermediate filament proteins. Lab Invest 1984;50:232-238.
34. Beckwith J, Palmer N. Histopathology and prognosis of Wilm's tumor: Results form the First National Wilm's Tumor Study. Cancer 1978;41:1937-1948.
35. Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P. Germline mutation of INI1/ SMARCB1 in familial schwannomatosis. Am J Hum Genet 2007;80:805-810.
36. Hadfield KD, Newman WG, Bowers NL, et al. Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. JMed Genet 2008;45:332-339.
37. Sestini R, Bacci C, Provenzano A, Genuardi M, Papi L. Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas. Hum Mutat 2008;29:227-231.
38. Vries RG, Bezrookove V, Zuijderduijn LM, et al. Cancer-associated mutations in chromatin remodeler hSNF5 promote chromosomal instability by compromising the mitotic checkpoint. Genes Dev 2005;19:665-670.
39. Tomasini R, Mak TW, Melino G. The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol 2008;18:244-252.
40. Lu X, Magrane G, Yin C, Louis D, Gray J, Van Dyke T. Selective inactivation of p53 facilitates mouse epithelial tumor progression without chromosomal instability. Mol Cell Biol 2001;21:6017-6030.
41. Aloyz R, Bamji S, Pozniak C, et al. p53 is essential for developmental neuron death as regulated by the TrkA and p75 neurotrophin receoptors. J Cell Biol 1998;143:1691-1703.
42. Xiang H, Hockman D, Saya H, Fujiwara T, Schwartzkroin P, Morrison R. Evidence for p53-mediated modulation of neuronal viability. J Neurosci 1996;16:6753-6765.